ANIKA THERAPEUTICS, INC.

Fourth Quarter 2016 Earnings Call Presentation

February 16, 2017



SAFE HARBOR STATEMENT


The statements made in this presentation that are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forwardlooking statements involve known and unknown risks, uncertainties, and other factors. The words "potential," "develop," "promising," "believe," "will," "would," "expect," "anticipate," "intend," "estimate," "plan," "likely," and other expressions, which are predictions of, or indicate future events and trends, and which do not constitute historical matters, identify forward-looking statements, including without limitation, management's discussion of the Company's growth and strategic plans. The Company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors including the results of its research and development efforts and the timing of regulatory approvals.



UPDATE ON DISCUSSIONS WITH FDA ON CINGAL



CINGAL® WAS SUPERIOR TO SALINE AT 26 WEEKS IN WOMAC PAIN SCORE DELIVERING A 72% (-42.4mm) IMPROVEMENT RELATIVE TO BASELINE



- Achieved Alignment on an Overall Approval Framework
- Submitted CINGAL IND Application in December 2016
- Commencement of a CINGAL Phase III Clinical Trial Expected in Q1 2017 with the first patient treated in Q2 2017



ADVANCING PIPELINE



^{*} In Pipeline in the U.S.; Approved in E.U.



- Non-woven HA Biodegradable 3D Scaffold for Cartilage Repair
- Cost-effective Single-step Procedure for the Repair of Articular Cartilage Defects
- Over 7,000 Treated with HYALOFAST Internationally
- FastTRACK Phase III Trial Ongoing for U.S. Approval



- Expanding Product Indication for Treatment of Hip OA Pain
- IDE Sponsored by U.S. Commercial Partner DePuy Synthes
- Potential to be First Therapy to Market for Hip OA Indication
- Phase III Trial Ongoing for U.S. Approval



EXPANDING GLOBALLY



- Commercial Launch of CINGAL in Canada and Europe Continues
- Currently Available in Approximately Ten Countries
- Finalizing CINGAL Regulatory Packages for India and Australia

ORTHOVISO)-T

- Received FDA Approval for IDE to Conduct Phase III Trial for Lateral Epicondylosis (Tennis Elbow)
- Received CE Mark Approval for ORTHOVISC-T in Q4 2016
- Commercial Launch in Europe Expected in 1H 2017
- Phase III Trial to Commence in Late 2017



STRENGTHENING INFRASTRUCTURE

- Integration of Solid HA Manufacturing Operations is Progressing as Planned
 - Build-out of the Bedford Facility has been Completed
 - Solid HA Product Packaging Operations Online Producing Enhanced Finished Goods
 - Fully Operational with Regulatory Approvals for Contract Manufacturing Transfer by Year-end 2017
- Progressing Build-out of New European Headquarters and Training Center in Padova, Italy



2017 BUSINESS OBJECTIVES

- Advance CINGAL, HYALOFAST and Other Development Programs for U.S. Approval
- Expand MONOVISC and CINGAL into New International Markets
- Commercially Launch ORTHOVISC-T in Europe
- Complete Consolidation of Global Manufacturing Operations
- Complete Build-out of New European Headquarters and Training Center in Padova, Italy
- Pursue Strategic M&A to Accelerate Expansion and Growth

CINGAL MONOVISC HyaloFast ORTHOVISC-T



DELIVERING STRONG GROWTH

Q4 & FY 2016 Financial Highlights

- **Product revenue** increased **11%** yearover-year for quarter; **17%** for year
- Orthobiologics revenue grew 13% yearover-year for quarter; 22% for year
- Net income of \$8.1M for quarter;
 \$32.5M for year
- Cash and investments of \$125M as of December 31, 2016

	Q4 2015	Q4 2016	FY 2015	FY 2016
Total Revenue	\$30.9	\$28.7	\$93.0	\$103.4
Net Income	\$11.0	\$8.1	\$30.8	\$32.5
Diluted EPS	\$0.72	\$0.54	\$2.01	\$2.15

Dollars in millions, except per-share amounts



FY 2017 GUIDANCE

	FY 2017 Guidance
Total Revenue Growth	Mid-Teen Percentage Growth
Operating Expenses	Increased R&D Spending to Advance Pipeline Investments to Strengthen Infrastructure
Capital Expenditures	\$8M - \$12M





Anika Therapeutics, Inc. Fourth Quarter 2016 Earnings Call Presentation

February 16, 2017

